Singer Jesy Nelson has announced a significant achievement in her campaign for Spinal Muscular Atrophy (SMA) Type 1 awareness, confirming that the screening test for the condition will now be implemented across the entire United Kingdom. Nelson expressed immense pride in the development, stating that the change will profoundly impact the lives of future babies diagnosed with SMA.
Nelson, whose 14-month-old twins Ocean and Story were diagnosed with SMA Type 1 in January, shared the update exclusively with the Daily Mail. "It's an emotional day. I'm still taking it in to be honest. It’s amazing. It's just mind-blowing. I feel so proud," Nelson said. "I just feel so proud of everyone that's been a part of getting it to this place because now future SMA baby’s lives are gonna look completely different. And that is all I ever wanted."
The announcement follows a previous parliamentary debate where the decision was made to only roll out newborn screening to 72% of the country, with the remaining 28% excluded. Nelson had previously expressed her disappointment and frustration with that outcome, describing herself as "absolutely fuming" and feeling "so let down."
However, the government has now confirmed the expansion of the screening program, which will begin in October. The SMA screening evaluation is moving faster than initially planned, with labs set to start testing babies for SMA in October 2026, three months ahead of schedule. Secretary of State for Health and Social Care, James Murray, emphasized the importance of early detection.
"No parent should have to watch their child lose the ability to move or breathe, knowing that earlier treatment could have made all the difference," Murray stated. "This expansion means babies across England will be tested from birth, giving them the best possible chance of a full and healthy life, and another step in the right direction as we do all we can to reduce health inequalities."
SMA is a rare genetic condition that weakens muscles. Type 1 SMA is the most severe form, often leading to death by age five if not treated early. Early diagnosis through a simple heel prick blood test allows for treatments that can significantly improve outcomes for affected children, enabling them to sit, crawl, and walk. Without early intervention, the condition can prevent babies from sitting up, crawling, or walking, and in severe cases, can impair breathing and swallowing.
Giles Lomax, Chief Executive Officer of SMA UK, lauded the development as a "hugely important step forward" after years of campaigning. He noted that when newborn screening begins in October, thousands of babies will benefit from earlier diagnosis and life-changing treatment. Lomax also expressed gratitude to the families, clinicians, researchers, supporters, and campaigners who contributed to this achievement, anticipating the day when all newborns across the UK receive the test.
Nelson reflected on how her daughters' experience has paved the way for this change, stating, "I feel super proud that my girls' story has been a part of change." She hopes to share this with her daughters when they are older, so they understand that their story contributed to a significant positive impact.
MUSCLE IMAGES:
